Bioinvent: Revealed the BI-1808 target

Research Note

2019-03-22

12:44

The company unveils that TNFR2 is the target for BI-1808, a receptor that predominantly is expressed on Tregs in the tumor microenvironment. According to Bioinvent, preclinical data are to be submitted for publication later this year. At this point, without any further data, it is not possible to have an opinion on the potential of BI-1808. It is an exciting target, and BI-1808 might be an attractive asset for partnering given its uniqueness.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.